Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB.

Gastroenterology. 2011 Apr;140(4):1314-21. doi: 10.1053/j.gastro.2010.12.038. Epub 2011 Jan 1.

PMID:
21199653
2.

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.

D'Avolio A, De Nicolò A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G.

Antiviral Res. 2013 Oct;100(1):114-9. doi: 10.1016/j.antiviral.2013.07.021. Epub 2013 Aug 8.

3.

Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.

Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ.

Antiviral Res. 2017 Feb;138:79-85. doi: 10.1016/j.antiviral.2016.12.005. Epub 2016 Dec 9.

PMID:
27956135
4.
5.

Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.

Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group (SCCS).

J Hepatol. 2013 Apr;58(4):669-75. doi: 10.1016/j.jhep.2012.11.027. Epub 2012 Nov 27.

6.

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.

Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, Vázquez-Morón S, Resino S.

J Transl Med. 2015 Oct 6;13:320. doi: 10.1186/s12967-015-0682-y.

7.

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.

Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M.

J Viral Hepat. 2014 Jul;21(7):466-74. doi: 10.1111/jvh.12171. Epub 2013 Sep 3.

PMID:
24750345
8.

Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.

Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ.

J Clin Pharmacol. 2017 Jan;57(1):118-124. doi: 10.1002/jcph.783. Epub 2016 Aug 4.

PMID:
27349952
9.

Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.

Peltenburg NC, Bakker JA, Vroemen WH, de Knegt RJ, Leers MP, Bierau J, Verbon A.

Clin Chem Lab Med. 2015 Nov;53(12):2021-9. doi: 10.1515/cclm-2015-0057.

PMID:
25968438
10.

Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.

Nemr N, Kishk R, Mandour M.

Indian J Gastroenterol. 2016 Jan;35(1):7-13. doi: 10.1007/s12664-016-0618-3. Epub 2016 Feb 16.

PMID:
26880169
11.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.

Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG, Goldstein DB, Soriano V.

J Infect Dis. 2012 Feb 1;205(3):376-83. doi: 10.1093/infdis/jir754. Epub 2011 Dec 9.

12.

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.

Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ, Janssen HL, Boonstra A, de Knegt RJ.

PLoS One. 2015 Oct 6;10(10):e0139317. doi: 10.1371/journal.pone.0139317. eCollection 2015.

13.

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG.

Gastroenterology. 2010 Oct;139(4):1181-9. doi: 10.1053/j.gastro.2010.06.016. Epub 2010 Jun 12.

14.

The effect of ITPA polymorphisms on the enzyme kinetic properties of human erythrocyte inosine triphosphatase toward its substrates ITP and 6-Thio-ITP.

Bakker JA, Lindhout M, Habets DD, van den Wijngaard A, Paulussen AD, Bierau J.

Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):839-49. doi: 10.1080/15257770.2011.606789.

PMID:
22060550
15.

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).

Birerdinc A, Estep M, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM.

J Viral Hepat. 2012 Jun;19(6):414-22. doi: 10.1111/j.1365-2893.2011.01564.x. Epub 2011 Dec 7.

PMID:
22571903
16.

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.

J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

PMID:
21503919
17.

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Tokunaga K, Mizokami M, Izumi N.

J Med Virol. 2013 Mar;85(3):449-58. doi: 10.1002/jmv.23497. Epub 2013 Jan 7.

PMID:
23297176
18.

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.

Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M.

J Gastroenterol. 2012 Nov;47(11):1228-37. doi: 10.1007/s00535-012-0579-y. Epub 2012 Mar 30.

PMID:
22460221
19.

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.

Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ.

CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):65-73. doi: 10.1002/psp4.12058. Epub 2016 Feb 2.

20.

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

Rallón NI, Morello J, Labarga P, Benito JM, Rodríguez-Nóvoa S, Vispo E, Barreiro P, Castro MÁ, Aguirrebengoa K, Pineda JA, Miralles P, Tellez MJ, Portu J, Miralles C, Ocampo A, Soriano V; Peginterferon Ribavirin Coinfection Team.

Clin Infect Dis. 2011 Dec;53(12):1291-5. doi: 10.1093/cid/cir665. Epub 2011 Oct 25.

PMID:
22028438

Supplemental Content

Support Center